trial
as of 2026-07-01Berberine in Treating Negative Symptoms of Schizophrenia: Clinical Efficacy and Mechanisms
NCTId NCT07356765
at a glance
— · Enrolling By Invitation
Enrollment 120 (estimated)
Sponsored by Tianjin Anding Hospital
Primary completion 2026-01
Synthesized from structured facts only — each point cited above.
Design & status
Phase
—
Status
Enrolling By Invitation
Enrollment
120 (estimated)
Study type
Interventional
Allocation
Randomized
Model
Parallel
Masking
Quadruple
Start
2023-09-26
Primary completion
2026-01
Eligibility
ALL · 18 Years · 60 Years
Interventions & indications
Sponsors
Tianjin Anding HospitalLead Sponsor
Shanghai Mental Health CenterCollaborator
Sites
1 total
Tianjin, China
Facts & assertions
4 sourced
Enrollment
120
Phase
NA
Primary Completion Date
2026-01
Status
ENROLLING_BY_INVITATION
relationships
The graph out of here
drug
drug
lead_sponsor
company
collaborator
indication